These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2154420)

  • 1. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
    Coleman CN; Noll L; Riese N; Buswell L; Howes AE; Loeffler JS; Alexander E; Wen P; Harris JR; Kramer RA
    Int J Radiat Oncol Biol Phys; 1992; 22(3):577-80. PubMed ID: 1531217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN; Urtasun RC; Wasserman TH; Hancock S; Harris JW; Halsey J; Hirst VK
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1749-53. PubMed ID: 6237086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
    Newman HF; Bleehen NM; Workman P
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
    Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Hirst VK; Hancock S; Phillips TL
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1105-8. PubMed ID: 3017904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
    Coleman CN; Buswell L; Noll L; Riese N; Rose MA
    Int J Radiat Oncol Biol Phys; 1992; 22(3):565-8. PubMed ID: 1310497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
    Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Bleehen NM; Newman HF; Maughan TS; Workman P
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Newman HF; Ward R; Workman P; Bleehen NM
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
    Coleman CN; Noll L; Howes AE; Harris JR; Zakar J; Kramer RA
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1085-7. PubMed ID: 2522919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
    Urtasun RC; Palmer M; Kinney B; Belch A; Hewitt J; Hanson J
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):337-42. PubMed ID: 9457818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
    Bleehen NM; Maughan TS; Workman P; Newman HF; Stenning S; Ward R
    Radiother Oncol; 1991; 20 Suppl 1():137-42. PubMed ID: 1826962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
    Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG).
    Wasserman TH; Lee DJ; Cosmatos D; Coleman N; Phillips T; Davis L; Marcial V; Stetz J
    Radiother Oncol; 1991; 20 Suppl 1():129-35. PubMed ID: 1826961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
    Maughan TS; Newman HF; Bleehen NM; Ward R; Workman P
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1151-6. PubMed ID: 2140825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.
    Workman P; Ward R; Maughan TS; Newman HF; Bleehen NM
    Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):177-81. PubMed ID: 2526107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxic cell radiosensitizers: expectations and progress in drug development.
    Coleman CN
    Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress report of a phase II and a phase III trial with etanidazole (SR-2508): a multicentre European study.
    Chassagne D; Sancho-Garnier H; Charreau I; Eschwege F; Malaise EP
    Radiother Oncol; 1991; 20 Suppl 1():121-7. PubMed ID: 1826960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Newman HF; Bleehen NM; Ward R; Workman P
    Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):677-84. PubMed ID: 2843488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.
    Murayama C; Suzuki A; Sato C; Tanabe Y; Miyata Y; Shoji T; Suzuki T; Sakaguchi M; Mori T
    Int J Radiat Oncol Biol Phys; 1992; 22(3):557-60. PubMed ID: 1531214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.